Annual EBITDA
-$17.84 M
-$2.72 M-18.00%
01 December 2023
Summary:
COSCIENS Biopharma annual earnings before interest, taxes, depreciation & amortization is currently -$17.84 million, with the most recent change of -$2.72 million (-18.00%) on 01 December 2023. During the last 3 years, it has fallen by -$9.31 million (-109.23%).CSCI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$5.37 M
-$3.87 M-258.45%
01 September 2024
Summary:
COSCIENS Biopharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$5.37 million, with the most recent change of -$3.87 million (-258.45%) on 01 September 2024. Over the past year, it has dropped by -$3.73 million (-227.61%).CSCI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$9.93 M
-$4.76 M-92.20%
01 September 2024
Summary:
COSCIENS Biopharma TTM earnings before interest, taxes, depreciation & amortization is currently -$9.93 million, with the most recent change of -$4.76 million (-92.20%) on 01 September 2024. Over the past year, it has dropped by -$7.00 million (-239.21%).CSCI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -227.6% | -239.2% |
| 3 y3 years | -109.2% | -492.7% | -336.4% |
| 5 y5 years | -93.3% | -1138.7% | -1544.7% |
CSCI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -289.4% | -333.5% | -238.3% |
COSCIENS Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$5.37 M(+258.5%) | -$9.93 M(+92.2%) |
| June 2024 | - | -$1.50 M(+4.7%) | -$5.17 M(+18.0%) |
| Mar 2024 | - | -$1.43 M(-12.7%) | -$4.38 M(+49.6%) |
| Dec 2023 | -$17.84 M(+18.0%) | -$1.64 M(+172.1%) | -$2.93 M(+174.5%) |
| Sept 2023 | - | -$602.00 K(-15.1%) | -$1.07 M(-228.2%) |
| June 2023 | - | -$709.00 K(-3444.3%) | $832.10 K(-77.9%) |
| Mar 2023 | - | $21.20 K(-90.5%) | $3.76 M(-37.7%) |
| Dec 2022 | -$15.12 M(+77.3%) | $223.40 K(-82.8%) | $6.04 M(-15.9%) |
| Sept 2022 | - | $1.30 M(-41.5%) | $7.18 M(+3.3%) |
| June 2022 | - | $2.22 M(-3.5%) | $6.95 M(+22.1%) |
| Mar 2022 | - | $2.30 M(+68.2%) | $5.69 M(+35.4%) |
| Dec 2021 | -$8.53 M(+127.1%) | $1.37 M(+28.4%) | $4.20 M(+42.4%) |
| Sept 2021 | - | $1.06 M(+10.6%) | $2.95 M(+21.9%) |
| June 2021 | - | $961.60 K(+18.8%) | $2.42 M(-7.9%) |
| Mar 2021 | - | $809.60 K(+603.4%) | $2.63 M(-11.5%) |
| Dec 2020 | -$3.75 M(-59.3%) | $115.10 K(-78.5%) | $2.97 M(-11.9%) |
| Sept 2020 | - | $534.40 K(-54.3%) | $3.37 M(+7.5%) |
| June 2020 | - | $1.17 M(+1.7%) | $3.14 M(+62.1%) |
| Mar 2020 | - | $1.15 M(+122.8%) | $1.94 M(+181.5%) |
| Dec 2019 | -$9.23 M(-198.0%) | $516.60 K(+72.3%) | $687.40 K(+47.6%) |
| Sept 2019 | - | $299.90 K(-1034.3%) | $465.60 K(-1163.0%) |
| June 2019 | - | -$32.10 K(-66.9%) | -$43.80 K(-56.6%) |
| Mar 2019 | - | -$97.00 K(-132.9%) | -$100.90 K(-52.8%) |
| Dec 2018 | $9.42 M(-146.5%) | $294.80 K(-240.7%) | -$213.80 K(-88.6%) |
| Sept 2018 | - | -$209.50 K(+134.9%) | -$1.87 M(+71.0%) |
| June 2018 | - | -$89.20 K(-57.5%) | -$1.09 M(+211.9%) |
| Mar 2018 | - | -$209.90 K(-84.6%) | -$350.90 K(+497.8%) |
| Dec 2017 | -$20.26 M(-30.6%) | -$1.36 M(-340.0%) | -$58.70 K(-103.8%) |
| Sept 2017 | - | $568.00 K(-13.2%) | $1.56 M(-10.9%) |
| June 2017 | - | $654.20 K(+694.9%) | $1.75 M(-41.8%) |
| Mar 2017 | - | $82.30 K(-67.3%) | $3.00 M(-30.8%) |
| Dec 2016 | -$29.20 M(-15.5%) | $251.40 K(-66.8%) | $4.33 M(-25.9%) |
| Sept 2016 | - | $757.80 K(-60.2%) | $5.85 M(-1.1%) |
| June 2016 | - | $1.91 M(+34.5%) | $5.91 M(+28.1%) |
| Mar 2016 | - | $1.42 M(-19.7%) | $4.61 M(+48.2%) |
| Dec 2015 | -$34.54 M(-5.4%) | $1.77 M(+115.0%) | $3.11 M(+122.4%) |
| Sept 2015 | - | $821.30 K(+34.4%) | $1.40 M(+7.9%) |
| June 2015 | - | $611.00 K(-834.4%) | $1.30 M(-7.0%) |
| Mar 2015 | - | -$83.20 K(-262.8%) | $1.40 M(-19.2%) |
| Dec 2014 | -$36.52 M(+37.7%) | $51.10 K(-92.9%) | $1.73 M(+4.3%) |
| Sept 2014 | - | $718.40 K(+1.3%) | $1.66 M(+45.5%) |
| June 2014 | - | $709.00 K(+186.0%) | $1.14 M(+316.2%) |
| Mar 2014 | - | $247.90 K(-1364.8%) | $273.50 K(-47.4%) |
| Dec 2013 | -$26.53 M(-6.9%) | -$19.60 K(-109.8%) | $520.30 K(+21.9%) |
| Sept 2013 | - | $201.00 K(-229.0%) | $426.80 K(+130.8%) |
| June 2013 | - | -$155.80 K(-131.5%) | $184.90 K(-33.4%) |
| Mar 2013 | - | $494.70 K(-537.4%) | $277.60 K(-321.7%) |
| Dec 2012 | -$28.50 M(-5.0%) | -$113.10 K(+176.5%) | -$125.20 K(-134.6%) |
| Sept 2012 | - | -$40.90 K(-35.2%) | $361.70 K(-9.9%) |
| June 2012 | - | -$63.10 K(-168.7%) | $401.60 K(-42.5%) |
| Mar 2012 | - | $91.90 K(-75.4%) | $698.20 K(-36.1%) |
| Dec 2011 | -$30.02 M(+40.0%) | $373.80 K(<-9900.0%) | $1.09 M(+7.8%) |
| Sept 2011 | - | -$1000.00(-100.4%) | $1.01 M(-19.0%) |
| June 2011 | - | $233.50 K(-52.0%) | $1.25 M(-7.8%) |
| Mar 2011 | - | $486.40 K(+65.3%) | $1.36 M(+40.4%) |
| Dec 2010 | -$21.44 M | $294.30 K(+24.4%) | $966.40 K(+23.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $236.50 K(-30.4%) | $780.80 K(+18.7%) |
| June 2010 | - | $339.70 K(+254.2%) | $658.00 K(+45.4%) |
| Mar 2010 | - | $95.90 K(-11.8%) | $452.70 K(-13.6%) |
| Dec 2009 | -$13.88 M(-73.0%) | $108.70 K(-4.4%) | $523.90 K(+25.5%) |
| Sept 2009 | - | $113.70 K(-15.4%) | $417.40 K(>+9900.0%) |
| June 2009 | - | $134.40 K(-19.6%) | $1000.00(-100.3%) |
| Mar 2009 | - | $167.10 K(+7495.5%) | -$361.10 K(-58.9%) |
| Dec 2008 | -$51.37 M(+76.0%) | $2200.00(-100.7%) | -$878.20 K(-22.2%) |
| Sept 2008 | - | -$302.70 K(+32.9%) | -$1.13 M(-1.3%) |
| June 2008 | - | -$227.70 K(-34.9%) | -$1.14 M(+30.7%) |
| Mar 2008 | - | -$350.00 K(+40.7%) | -$875.90 K(+112.2%) |
| Dec 2007 | -$29.19 M(+98.9%) | -$248.70 K(-21.8%) | -$412.70 K(-18.0%) |
| Sept 2007 | - | -$318.10 K(-877.8%) | -$503.50 K(+219.5%) |
| June 2007 | - | $40.90 K(-63.9%) | -$157.60 K(+155.0%) |
| Mar 2007 | - | $113.20 K(-133.3%) | -$61.80 K(-51.8%) |
| Dec 2006 | -$14.68 M(+357.0%) | -$339.50 K(-1321.2%) | -$128.10 K(-131.2%) |
| Sept 2006 | - | $27.80 K(-79.7%) | $411.10 K(+2.8%) |
| June 2006 | - | $136.70 K(+191.5%) | $399.80 K(+18.9%) |
| Mar 2006 | - | $46.90 K(-76.5%) | $336.20 K(+88.6%) |
| Dec 2005 | -$3.21 M(+332.3%) | $199.70 K(+1110.3%) | $178.30 K(-202.7%) |
| Sept 2005 | - | $16.50 K(-77.4%) | -$173.60 K(-56.1%) |
| June 2005 | - | $73.10 K(-165.9%) | -$395.50 K(-24.1%) |
| Mar 2005 | - | -$111.00 K(-27.1%) | -$521.40 K(+22.9%) |
| Dec 2004 | -$743.00 K(-78.1%) | -$152.20 K(-25.9%) | -$424.10 K(+68.6%) |
| Sept 2004 | - | -$205.40 K(+289.0%) | -$251.60 K(+100.3%) |
| June 2004 | - | -$52.80 K(+285.4%) | -$125.60 K(+1001.8%) |
| Mar 2004 | - | -$13.70 K(-167.5%) | -$11.40 K(-81.4%) |
| Dec 2003 | -$3.40 M(-70.5%) | $20.30 K(-125.6%) | -$61.30 K(-60.3%) |
| Sept 2003 | - | -$79.40 K(-229.3%) | -$154.40 K(+15.6%) |
| June 2003 | - | $61.40 K(-196.5%) | -$133.60 K(+97.1%) |
| Mar 2003 | - | -$63.60 K(-12.6%) | -$67.80 K(-47.9%) |
| Dec 2002 | -$11.53 M(+15.4%) | -$72.80 K(+24.2%) | -$130.10 K(-39.5%) |
| Sept 2002 | - | -$58.60 K(-146.1%) | -$214.90 K(+7.9%) |
| June 2002 | - | $127.20 K(-201.0%) | -$199.20 K(-58.9%) |
| Mar 2002 | - | -$125.90 K(-20.1%) | -$484.40 K(+13.8%) |
| Dec 2001 | -$9.99 M(+33.6%) | -$157.60 K(+267.4%) | -$425.80 K(-19.8%) |
| Sept 2001 | - | -$42.90 K(-72.8%) | -$531.10 K(-2.7%) |
| June 2001 | - | -$158.00 K(+134.8%) | -$545.90 K(+19.9%) |
| Mar 2001 | - | -$67.30 K(-74.4%) | -$455.40 K(-13.4%) |
| Dec 2000 | -$7.48 M(+19.2%) | -$262.90 K(+355.6%) | -$525.80 K(-11.7%) |
| Sept 2000 | - | -$57.70 K(-14.5%) | -$595.50 K(-1.7%) |
| June 2000 | - | -$67.50 K(-51.0%) | -$605.90 K(-10.1%) |
| Mar 2000 | - | -$137.70 K(-58.6%) | -$674.10 K(+11.8%) |
| Dec 1999 | -$6.27 M(+69.4%) | -$332.60 K(+388.4%) | -$602.70 K(-16.3%) |
| Sept 1999 | - | -$68.10 K(-49.8%) | -$720.40 K(-8.0%) |
| June 1999 | - | -$135.70 K(+104.7%) | -$783.30 K(-0.1%) |
| Mar 1999 | - | -$66.30 K(-85.3%) | -$783.70 K(-15.6%) |
| Dec 1998 | -$3.70 M(+278.7%) | -$450.30 K(+243.7%) | -$928.70 K(-40.8%) |
| Sept 1998 | - | -$131.00 K(-3.7%) | -$1.57 M(-29.8%) |
| June 1998 | - | -$136.10 K(-35.6%) | -$2.23 M(-29.8%) |
| Mar 1998 | - | -$211.30 K(-80.6%) | -$3.18 M(-18.7%) |
| Dec 1997 | -$978.30 K(-48.4%) | -$1.09 M(+36.9%) | -$3.92 M(+38.6%) |
| Sept 1997 | - | -$796.30 K(-26.7%) | -$2.82 M(+39.3%) |
| June 1997 | - | -$1.09 M(+15.3%) | -$2.03 M(+115.3%) |
| Mar 1997 | - | -$942.10 K | -$942.10 K |
| Dec 1996 | -$1.90 M | - | - |
FAQ
- What is COSCIENS Biopharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly EBITDA year-on-year change?
- What is COSCIENS Biopharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for COSCIENS Biopharma?
- What is COSCIENS Biopharma TTM EBITDA year-on-year change?
What is COSCIENS Biopharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CSCI is -$17.84 M
What is the all time high annual EBITDA for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual earnings before interest, taxes, depreciation & amortization is $9.42 M
What is COSCIENS Biopharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CSCI is -$5.37 M
What is the all time high quarterly EBITDA for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $2.30 M
What is COSCIENS Biopharma quarterly EBITDA year-on-year change?
Over the past year, CSCI quarterly earnings before interest, taxes, depreciation & amortization has changed by -$3.73 M (-227.61%)
What is COSCIENS Biopharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CSCI is -$9.93 M
What is the all time high TTM EBITDA for COSCIENS Biopharma?
COSCIENS Biopharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $7.18 M
What is COSCIENS Biopharma TTM EBITDA year-on-year change?
Over the past year, CSCI TTM earnings before interest, taxes, depreciation & amortization has changed by -$7.00 M (-239.21%)